Measures of biosimilarity in monoclonal antibodies in oncology: The case of bevacizumab

Drug Discovery Today

Volumn 18, Issue 17-18, 2013, Pages 872-879

  Ebbers, Hans C ^a   Van Meer, Peter J K ^a   Moors, Ellen H M ^b   Mantel Teeuwisse, Aukje K ^a   Leufkens, Hubert G M ^a   Schellekens, Huub ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOSIMILAR AGENT; CAPECITABINE; FLUOROURACIL; IRINOTECAN; RANIBIZUMAB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTERY THROMBOSIS; BIOEQUIVALENCE; BLEEDING; BREAST CANCER; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; DIGESTIVE SYSTEM PERFORATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; IMMUNOGENICITY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; METASTATIC COLORECTAL CANCER; NEUTROPENIA; NONHUMAN; ONCOLOGY; OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; REVIEW; VEIN THROMBOSIS; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOSIMILAR PHARMACEUTICALS; DRUG EVALUATION, PRECLINICAL; HUMANS; PATENTS AS TOPIC; PATIENT SAFETY; QUALITY CONTROL; RISK ASSESSMENT; RISK FACTORS; THERAPEUTIC EQUIVALENCY;

EID: 84883214584     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.05.004     Document Type: Review

References (55)

1. M. McCamish, and G. Woollett The state of the art in the development of biosimilars Clin. Pharmacol. Ther. 91 2012 405 417
2. A. Mullard Can next-generation antibodies offset biosimilar competition? Nat. Rev. Drug Discov. 11 2012 426 428
3. H. Ledford 'Biosimilar' drugs poised to penetrate market Nature 468 2010 18 19
4. European Medicines Agency Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues 2012 Available from: http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2012/06/WC500128686.pdf [Accessed July 16, 2012]
5. L.G. Presta Humanization of an antibody directed against IgE J. Immunol. 151 1993 2623 2632
6. S.M. Weis, and D.A. Cheresh Tumor angiogenesis: molecular pathways and therapeutic targets Nat. Med. 17 2011 1359 1370
7. P. Correa de Sampaio A heterogeneous in vitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis PLoS ONE 7 2012 E30753
8. P. Borgstrom Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo Prostate 35 1998 1 10
9. L. Hu Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer Am. J. Pathol. 161 2002 1917 1924
10. O. Melnyk Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model J. Urol. 161 1999 960 963
11. S. Mesiano Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization Am. J. Pathol. 153 1998 1249 1256
12. S.Z. Soffer Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor J. Pediatr. Surg. 36 2001 1177 1181
13. R.S. Warren Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis J. Clin. Invest. 95 1995 1789 1797
14. C.G. Begley, and L.M. Ellis Drug development: raise standards for preclinical cancer research Nature 483 2012 531 533
15. L.R. Kelland Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development Eur. J. Cancer 40 2004 827 836
16. R. Deng Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin. Drug Metab. Toxicol. 8 2012 141 160
17. M.S. Gordon Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J. Clin. Oncol. 19 2001 843 850
18. K. Margolin Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data J. Clin. Oncol. 19 2001 851 856
19. J.F. Lu Clinical pharmacokinetics of bevacizumab in patients with solid tumors Cancer Chemother. Pharmacol. 62 2008 779 786
20. S. Tanaka Statistical issues and recommendations for noninferiority trials in oncology: a systematic review Clin. Cancer Res. 18 2012 1837 1847
21. European Medicines Agency Guideline on the choice of the non-inferiority margin 2005 Available from: http://www.emea.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003636.pdf [Accessed 1 Aug 2012]
22. European Medicines Agency Guideline on the evaluation of anticancer medicinal products in man (CPMP/EWP/205/95/Rev.3/Corr.2) 2012
23. H.J. Schmoll ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Ann. Oncol. 23 10 2012 2479 2516
24. L.B. Saltz Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J. Clin. Oncol. 26 2008 2013 2019
25. A.M. Jubb, and A.L. Harris Biomarkers to predict the clinical efficacy of bevacizumab in cancer Lancet Oncol. 11 2010 1172 1183
26. H. Hurwitz Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 2004 2335 2342
27. J.J. Mourad Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation Ann. Oncol. 19 2008 927 934
28. M. Scartozzi Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab Ann. Oncol. 20 2009 227 230
29. P. Osterlund Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy Br. J. Cancer 104 2011 599 604
30. A. De Stefano Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients Cancer Chemother. Pharmacol. 68 2011 1207 1213
31. A. Dewdney Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection Br. J. Cancer 106 2012 1718 1721
32. E. Tahover P 0214 hypertension as a predictive biomarker in bevacizumab Ann. Oncol. 23 Suppl. 4 2012 iv91
33. B.L. Burnette, and A. Grothey Hypertension and survival in unresectable metastatic colorectal cancer (mCRC) patients receiving first-line bevacizumab (BEV) and FOLFOX J. Clin. Oncol. 28 2010 e14066 (Abstract)
34. H. Hurwitz Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV) J. Clin. Oncol. 28 2010 (abstr 3039)
35. L. Horsley Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy Expert Opin. Drug Metab. Toxicol. 8 2012 283 293
36. X. Zhu Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis Am. J. Kidney Dis. 49 2007 186 193
37. E. Saloustros Favorable clinical course of patients experiencing bevacizumab-induced proteinuria Case Rep. Oncol. 3 2010 368 371
38. S. Wu Bevacizumab increases risk for severe proteinuria in cancer patients J. Am. Soc. Nephrol. 21 2010 1381 1389
39. S. Hapani Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis Oncology 79 2010 27 38
40. A. Gerger Molecular predictors of response to antiangiogenesis therapies Cancer J. 17 2011 134 141
41. N. Steeghs Reversibility of capillary density after discontinuation of bevacizumab treatment Ann. Oncol. 21 2010 1100 1105
42. The IVAN Study Investigators Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
43. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N. Engl. J. Med. 364 2011 1897 1908
44. P.J. Rosenfeld Ranibizumab for neovascular age-related macular degeneration N. Engl. J. Med. 355 2006 1419 1431
45. A.M. Goodwin In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents Microvasc. Res. 74 2007 172 183
46. L. Yu Comparing protein VEGF inhibitors: in vitro biological studies Biochem. Biophys. Res. Commun. 408 2011 276 281
47. A. Barzelay Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis Curr. Eye Res. 35 2010 835 841
48. A. Klettner, and J. Roider Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways Invest. Ophthalmol. Vis. Sci. 49 2008 4523 4527
49. H.C. Ebbers Effective pharmaceutical regulation needs alignment with doctors Drug Discov. Today 17 2012 100 103
50. N. Ferrara The biology of VEGF and its receptors Nat. Med. 9 6 2003 669 676
51. B. Escudier Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
52. A. Sandler Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N. Engl. J. Med. 355 2006 2542 2550
53. T.J. Perren A phase 3 trial of bevacizumab in ovarian cancer N. Engl. J. Med. 365 2011 2484 2496
54. N.J. Robert RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J. Clin. Oncol. 29 2011 1252 1260
55. T. Filleron Designing group sequential randomized clinical trials with time to event end points using a R function Comput. Methods Prog. Biomed. 108 2012 113 128